Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Avecho Biotechnology Limited ( (AU:AVE) ) is now available.
Avecho Biotechnology has announced that CEO Dr Paul Gavin will present at the Euroz Hartleys Healthcare Forum, where he will provide an update on the company’s pivotal Phase III clinical trial of its CBD TPM soft-gel capsule for insomnia and outline its 2026 outlook. The large, multi-centre trial—designed to meet regulatory standards in Australia, the US and Europe—is approaching completion of recruitment ahead of an interim analysis and represents the final clinical step before a potential submission to the Australian Therapeutic Goods Administration for registration of the insomnia treatment. With no other successful Phase III CBD insomnia trials in Australia to date and a regulatory framework that permits over-the-counter CBD sales through pharmacies once approved, a positive outcome could give Avecho a first-mover advantage in a sizeable and growing sleep-disorder market, positioning the company to capitalise on rising recognition of sleep health as a national priority and the expanding global sleep-economy and CBD sectors.
The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian drug delivery company that develops and commercialises human and animal health products using its proprietary Tocopheryl Phosphate Mixture (TPM), a vitamin E-derived technology designed to enhance the solubility and absorption of drugs and nutrients via oral, dermal and transdermal routes. Its lead asset is a TPM-enhanced cannabidiol (CBD) soft-gel capsule in Phase III clinical development for insomnia, alongside broader programs applying TPM to injectables, oral and topical formulations for human health and to improve feed efficiency and livestock health.
Average Trading Volume: 6,406,599
Technical Sentiment Signal: Sell
Current Market Cap: A$36.73M
For detailed information about AVE stock, go to TipRanks’ Stock Analysis page.